Vectura Group plc researches, develops, and commercialises novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company offers ADVATE for the treatment of haemophilia A; Adept for the treatment of surgical adhesions; Extraneal for the treatment of peritoneal dialysis; Seebri Breezhaler and Ultibro Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); and AirFlusal Forspiro for the treatment of asthma and COPD, as well as Asmasal and Asmabec for the treatment of asthma. Its full development stage products include VR315, VR506, and VR632 for the treatment of asthma. The company’s Phase III clinical stage products include NVA237 and QVA149 for the treatment of COPD; VR475 for the treatment severe adult asthma; and VR876 for the treatment of pulmonary hypertension. Its Phase II clinical stage products comprise VR647 for the treatment of paediatric asthma; VR179 for the treatment of cystic fibrosis; VR736 for the treatment severe influenza; and SB010 for the treatment of asthma and other respiratory diseases. The company’s Phase I clinical stage products include VR475 for the treatment severe adult asthma; VR465 for the treatment for respiratory syncytial virus infection. Its pre-clinical stage products include VR588 and VR942 for the treatment of inflammatory airway diseases; and VR611 for the treatment of airways inflammatory and chronic cough diseases. The company also provides drug delivery technology platforms, such as PowderHale, a dry powder inhalation (DPI) formulation technology that is designed to enhance the performance of DPI products; PowderMax technology that applies PowderHale approach to spectrum of drug substances; and ParticleMax technology to create a new generation of formulations. In addition, it provides Gryohaler, lever-operated, open-inhale-close, AKITA Jet, APIXNEB, and FOX devices. The company was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
vectura group plc
(VEC:London Stock Exchange)
One Prospect West
Chippenham, SN14 6FH
Phone: 44 1249 667700
Fax: 44 1249 667701www.vectura.co.uk
|No competitor information is available for VEC.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact VECTURA GROUP PLC, please visit www.vectura.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.